WELDING PHARMA API and CHEMISCHE FABRIK BERG Announce Exclusive Partnership for Lisdexamfetamine

WELDING PHARMA API is proud to announce an exclusive partnership with CHEMISCHE FABRIK BERG for the development, manufacture and commercialization of Lisdexamfetamine dimesilate. Building on more than two decades of trusted collaboration in pharmaceutical APIs, this strategic partnership marks a Mehr

Deepening Technical Expertise in Pet Food

WELDING FEED, part of the WELDING Group, is deepening its collaboration with WELDING FOOD and its partner Eurogum – Bang & Bonsomer. By combining feed and food expertise, the partners support pet food manufacturers in developing reliable, high-quality products. Following Mehr

Quinine 200 mg Film-Coated Tablets (DCP Start)

  Quinine 200 mg Film-Coated Tablets (DCP Start) The company has started the Decentralized Procedure (DCP) for Quinine 200 mg Film-Coated Tablets, marking a new step in the expansion of its European generic portfolio. Building on decades of experience in Mehr

WELDING GmbH & Co. KG, through its business unit PHARMA FDF, announces its first European marketing authorizations for Tafamidis 61 mg soft capsules

WELDING GmbH & Co. KG announces an important regulatory milestone in Europe. Following the successful closure of the Decentralized Procedure (DCP) earlier this year, WELDING GmbH & Co. KG in collaboration with its partner Zenara Pharma Pvt Ltd has received its Mehr

WELDING GmbH & Co. KG Expands to Latin America

WELDING GmbH & Co. KG announces the establishment of its Mexican subsidiary, WELDING Ingredientes SA de CV. With this step, our family-owned company is expanding its international presence and strengthening its position in the Latin American market. Our goal is Mehr

Revio Therapeutics and Welding Group Announce Strategic Co-Development and Licensing Agreement for Innovative Specialty Oncology Product

Revio Therapeutics ("Revio") and Welding Group ("Welding") today announced the signing of a co-development and licensing agreement for Revio’s proprietary specialty oncology product. The 505(b)(2) product, designed based on an innovative dosage form with significant patient compliance and ease-of-use advantages, will be developed Mehr